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Abstract. The aim of the study was to verify by Ki-67
immunostaining if any difference exists in the cell proliferating
fraction between primary breast tumors (PTs) and matching
positive axillary lymph nodes (ALNs). Patients and Methods:
Immunohistochemistry with the monoclonal antibody against Ki-
67 was performed in 160 node-positive breast carcinomas and in
their respective lymph node metastases. Results: An increase of
Ki-67 immunoreactive cells in ALN compared with that of PTs
was observed in 84% of cases (ALN: mean 17%, PTs: mean
8%; p<0.001), whereas 16% of the cases showed Ki-67 value
two to six times lower in the ALNs than in the corresponding PTs
(ALN: mean 3.2%, PTs mean 12.5%; p<0.005). The decrease
of Ki-67 positive cells in the ALN was independent from the
histotype and the histological grade of the tumor. Conclusion: A
different cell proliferation fraction between PTs and matching
positive ALNs was demonstrated and underlined that the
existence of a group of patients with decreased number of Ki-67
immunoreactive cells in lymph node metastases compared with
that of the primary tumors could be taken into account in the
choice of therapeutic strategy.
Breast cancer is the first cause of death in women. Its
biological behavior is highly variable and many efforts have
been made over the years to further characterize this
neoplasia, its potential aggressiveness and the probability of
response to treatment.
The most important prognostic factors in breast cancer are
the expression of estrogen and progesterone receptors, 
C-Erb2, p53 and the proliferation index (PI). The PI is usually
assessed through the immmunohistochemical evaluation of
Ki-67, a monoclonal antibody which reacts with a nuclear
antigen expressed in all the proliferating cells during the active
phase of the cell cycle (G1, S, G2), and which is absent in G0
cells. The PI has a strong prognostic value even when
considered alone (1) and plays a role in determining the
efficacy of some chemotherapic agents (i.e., 5-fluorouracil)
that are generally cell-cycle dependent.
To date, immunohistochemical prognostic factors have
been studied exclusively on primary tumors and their
assessment has influenced the therapeutic strategies. 
The purpose of this study was to verify, by Ki-67
immunostaining in primary breast tumors (PTs) and in
matching positive axillary lymph nodes (ALNs), if any
difference exists in the cell proliferating fraction of these two
different breast cancer locations.
Patients and Methods
One hundred and sixty cases of PTs with diameters ranging from 2
to 5 cm (T2 according to the UICC-TNM staging system) and with
positive ALNs, were consecutively selected between 2002 and 2005,
from the Institute of Pathology of the University of Palermo (Italy).
The cases consisted of 96 ductal infiltrating carcinomas (80 CDI, 9
mucinous carcinomas, 7 apocrine carcinomas), 51 lobular infiltrating
carcinomas, 7 lobular and ductal infiltrating carcinomas and 6 tubulo-
lobular carcinomas. Informed consent was obtained from all the
patients included in the study.
The immunohistochemical evaluation was performed on tissue
sections from formalin-fixed, paraffin-embedded samples from the
PTs and corresponding ALNs. Tissue sections were treated using a
microwave epitope retrieval technique with 10 mmol/L citrate buffer,
pH 6.0, at high temperature for 20 min and were then incubated with
antibody against Ki-67 by the avidin-biotin-peroxidase complex
method. Appropriate positive controls were run concurrently for the
antibody tested. In all cases, a subjective, qualitative evaluation of the
areas showing the highest positivity for Ki-67 was carried out. In each
case, approximately 10 non-overlapping high power fields (objective
40x) were selected from three section planes of the tissue block.
High-power fields were accepted for evaluation when they did not
contain areas of extensive necrosis, unspecific background staining or
sectioning artefacts. The percentage of positive cells was counted in at
least 1,000 tumoral cells, both in PTs and their matching ALNs, by
two pathologists independently. 
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To assess the difference in Ki-67 expression between PTs and
ALNs, statistical analysis was performed by the means of Student’s t-
test for paired independent samples.
Results
The immunoreactivity of the Ki-67 antibody was distributed
in two categories (Table I). 
Category A consisted of 135 cases (84%) of the following
histological types: 68 infiltrating ductal carcinomas NOS
(Elston and Ellis system scoring: grade 1=24 cases; grade
2=27 cases; grade 3=17 cases), 7 mucinous carcinomas, 5
apocrine carcinomas, 48 infiltrating lobular carcinomas, 3
lobular and ductal infiltrating carcinomas and 4 tubulo-lobular
carcinomas. All cases showed an increased number of Ki-67-
immunoreactive cells in ALNs compared to the PTs (ALN:
mean 17%, range 10-23%; PTs: mean 8%, range 3-13%; mean
difference 9%; p<0.001).
Category B consisted of 25 cases (16%) of the following
histological types: 12 infiltrating ductal carcinomas NOS
(Elston and Ellis system scoring: grade 1=4 cases; grade 2=5
cases; grade 3=3 cases), 2 mucinous carcinomas, 2 apocrine
carcinomas, 7 infiltrating lobular carcinomas, 1 lobular and
ductal infiltrating carcinoma and 1 tubulo-lobular carcinoma.
In this category, the cases showed a decreased number of 
Ki-67 immunoreactive cells in the ALNs compared to the PTs
(ALN: mean 3.2%, range 2-5%; PTs: mean 12.5%, range 
5-23%; mean difference 9.3%; p<0.005).
In category B, the ALNs showed a percentage of Ki-67-
positive cells two to six times lower than that observed in the
corresponding PTs (PT/ALN ratio=3.7; range=2-6.5). The
decrease of Ki-67-positive cells in the ALN proved to be
independent from the histotype and the histological grade of
the tumor.
Figure 1 shows the increase of Ki-67 immunostaining in
ALN compared to the PT in a case from category A (Figure
1a-b) and the decrease of Ki-67 immunostaining in ALN
compared to the PT in a case from category B (Figure 1c-d).
The distribution of the 160 cases according to the PI in PT
and ALN, is shown in Figure 2. Those cases with a higher PI
in ALN (classic) and those with a higher PI in PT (variant)
show a distinct distribution.
When the 160 selected cases were analyzed as a whole, the
mean percentage of Ki-67 immunoreactive cells was
significantly higher in the ALNs than in the PTs (ALN: mean
15%, range 2-30; PTs: mean 9%, range 3-36%. The mean
difference was 6%; p<0.001).
Discussion
Breast cancer has a very high frequency worldwide and is the
first cause of death in women. The median survival of
metastatic breast cancer ranges from 2 to 3 years, although
there is a wide variability among the patients. The activity of
some of the commonly used chemotherapic agents (i.e., 5-
fluorouracil, cyclophospamide, methotrexate, anthracyclines)
is generally cell-cycle dependent and, thus, cell growth
fraction, assessed by Ki-67, could play a role in the efficacy of
these drugs (2).
In primary breast tumors, the PI (assessed by Ki-67) is
significantly associated with the PT stage, the axillary lymph
node status and the tumor grading, and is inversely related to
progesterone and estrogen receptor status (1-4). To date, Ki-
67 and the other immunohistochemical prognostic factors
(estrogen and progesterone receptors, C-Erb2, p53) are
exclusively assessed by the primary tumor. Recently,
differential expression of these molecular markers has been
shown between invasive mammary ductal carcinoma
associated with ductal carcinoma in situ versus invasive breast
cancer alone, confirming the important role of these markers
in tumor progression (5).
Fehm et al. (6) showed that the bone marrow involvement
was not influenced by tumor size and lymph node
involvement, but it was significantly related to p53 expression,
hormone receptor status, HER2 and Ki-67 in keeping the role
of tumor biological factors of the primary tumor for tumor cell
dissemination.
De la Haba-Rodriguez et al. (7) reported that in 60% of
their cases, the immunohistochemical expression of some
proteins, such as estrogen, progesterone, Ki-67, p53 and HER-
2, was modified during tumor development and dissemination,
and led to immunophenotypical differences between PTs and
ALNs. They suggested that this could be related to the intrinsic
hetereogeneity of the neoplastic cells. In addition, it was also
suggested that as different clones are present in primary breast
carcinomas, it is possible that only a small sub-population of
the PT cells metastasize (3).
Buxant et al. found a significantly higher PI in ALNs than in
PTs, suggesting an increased aggressiveness of metastatic
neoplastic cells compared to their PT counterpart. They
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Table I. Mean percentage of Ki-67 immunoreactive cells in primary tumors (PTs) and in matching axillary lymph nodes metastases (ALNs).
PTs (%)   range ALNs (%)  range difference (%) p-value
Category A (135 cases) 8 (3-13) 17 (10-23) 9 <0.001
Category B ( 25 cases) 12.5 (5-23) 3.2 (2-5) 9.3 <0.005
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concluded that those cells with "the most aggressive potential
(i.e., high PI) were the most likely to escape from the primary
tumor" or, that "cells that escape from primary tumor, lose
down-regulator factors or suppressor genes and become more
aggressive" (2).
In our study, the mean Ki-67 value was found to be higher
in ALNs than in PTs when considering all the cases as a whole
(ALN: mean 15%, range 2-30; PTs: mean 9%, range 3-36%;
mean difference: 6%; p<0.001). Our results, obtained from the
statistical analysis of Ki-67 mean values of PTs and ALNs, fit
well with those of the Buxant et al. study (2), showing that the
mean Ki-67 value was higher in PTs than in ALNs.
Nevertheless, it is important to note a minority of cases
included in the B category, in which the cell growing fraction
(assessed by Ki-67 immunostaining) was significantly decreased
in ALNs as compared to the PTs. In these cases, the Ki-67
value in the ALNs was two to six times lower than that in the
corresponding PTs (PT/ALN ratio=3.7; range=2-6.5).
It is still unclear why some metastatic cells, which should
have an elevated cell growth fraction because of their high
aggressiveness, show a PI lower than that of PT cells. Perhaps
their aggressiveness is related to other biological factors,
which should be assessed in further specific studies. However,
since the efficacy of chemotherapy is generally cell-cycle
dependent, lower values of Ki-67 immunoreactivity in ALNs
(revealing a majority of cells in G0-phase) could influence the
clinician’s therapeutic choice. Further studies are necessary to
understand the importance of heterogeneity between PTs and
ALNs, as well as the clinical relevance of assessing the cell
growing fraction in ALNs. 
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Figure 2. Distribution of cases according to the proliferation index in primary tumors and in axillary lymph nodes.
